New approaches and therapeutics targeting apoptosis in disease

Pharmacological Reviews

Volumn 57, Issue 2, 2005, Pages 187-215

  Fischer, Ute ^a   Schulze Osthoff, Klaus ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; 4' CHLORODIAZEPAM; ADALIMUMAB; ANTINEOPLASTIC AGENT; APOPTIN; CASPASE 3 INHIBITOR; CASPASE 7 INHIBITOR; CASPASE 9 INHIBITOR; CASPASE INHIBITOR; CENTOCOR; DEATH RECEPTOR; DOXORUBICIN; ETANERCEPT; IDN 11104; IDN 6734; INFLIXIMAB; ISATIN DERIVATIVE; ISIS 104838; M 791; M 826; M 920; MX 1013; MX 2060; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PRALNACASAN; PRO 1762; PROTEASOME; PROTEIN BCL 2; TRAIL RECEPTOR 1 ANTIBODY; TRAIL RECEPTOR 2 ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 765; VX 799; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CELL DEATH; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; ENTERITIS; ENZYME INHIBITION; HUMAN; LYMPHOMA; MELANOMA; MITOCHONDRION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RHEUMATOID ARTHRITIS; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ANIMALS; APOPTOSIS; DISEASE; DRUG DESIGN; DRUG THERAPY; HUMANS;

EID: 22944473652     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.57.2.6     Document Type: Review

References (220)

1. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, and Stein RL (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333-338.
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, and Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622.
3. Allen DA, Pham P, Choong IC, Fahr B, Burdett MT, Lew W, DeLano WL, Gordon EM, Lam JW, O'Brien T, and Lee D (2003) Identification of potent and novel small-molecule inhibitors of caspase-3. Bioorg Med Chem Lett 13:3651-3655.
4. Ambrosini G, Adida C, and Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921.
5. An WG, Hwang SG, Trepel JB, and Blagosklonny MV (2000) Protease inhibitorinduced apoptosis: accumulation of wt p53, p21WAF1/CIP1 and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14:1276-1283.
6. An WG, Schnur RC, Neckers L, and Blagosklonny MV (1997) Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 40:60-64.
7. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, et al. (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8:121-127.
8. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, and Kaufmann SH (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 277:44236-44243.
9. Asgian JL, James KE, Li ZZ, Carter W, Barrett AJ, Mikolajczyk J, Salvesen GS, and Powers JC (2002) Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases. J Med Chem 45:4958-4960.
10. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investig 104:155-162.
11. Baens M, Maes B, Steyls A, Geboes K, Marynen P, and De Wolf-Peeters C (2000) The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 156:1433-1439.
12. Becker JW, Rotonda J, Soisson SM, Aspiotis R, Bayly C, Francoeur S, Gallant M, Garcia-Calvo M, Giroux A, Grimm E, et al. (2004) Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis. J Med Chem 47:2466-2474.
13. Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M, Schulze-Osthoff K, and Budach W (2001) Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 20:2190-2196.
14. Belzacq AS, Jacotot E, Vieira HL, Mistro D, Granville DJ, Xie Z, Reed JC, Kroemer G, and Brenner C (2001) Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res 61:1260-1264.
15. Berenson JR, Ma HM, and Vescio R (2001) The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 28:626-633.
16. Bilim V, Kasahara T, Hara N, Takahashi K, and Tomita Y (2003) Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of IAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 103:29-37.
17. Blagosklonny MV, Toretsky J, and Neckers L (1995) Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11:933-939.
18. Bold RJ, Virudachalam S, and McConkey DJ (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100:11-17.
19. Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, et al. (2000) A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin Cancer Res 6:42-49.
20. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, Simmons DL, Akbar AN, Lord JM, and Salmon M (1999) RGD peptides induce apoptosis by direct caspase-3 activation. Nature (Lond) 397:534-539.
21. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, and Ores M (2005) Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets 5:57-68.
22. Butz K, Denk C, Ullmann A, Scheffner M, and Hoppe-Seyler F (2000) Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 97:6693-6697.
23. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, and Selivanova G (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288.
24. Cai SX, Guan L, Jia S, Wang Y, Yang W, Tseng B, and Drewe J (2004) Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group. Bioorg Med Chem Lett 14:5295-5300.
25. Campos L, Sabido O, Rouault JP, and Guyotat D (1994) Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595-600.
26. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, and Gores GJ (2004) The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 308:1191-1196.
27. Caserta TM, Smith AN, Gultice AD, Reedy MA, and Brown TL (2003) Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8:345-352.
28. Chan SL, Lee MC, Tan KO, Yang LK, Lee AS, Flotow H, Fu NY, Butler MS, Soejarto DD, Buss AD, and Yu VC (2003) Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 278:20453-20456.
29. Chapman JG, Magee WP, Stukenbrok HA, Beckius GE, Milici AJ, and Tracey WR (2002) A novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2- methoxymethylpyrrolidinyl) sulfonyl]isatin reduces myocardial ischemic injury. Eur J Pharmacol 456:59-68.
30. Chene P, Fuchs J, Bohn J, Garcia-Echeverria C, Furet P, and Fabbro D (2000) A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J Mol Biol 299:245-253.
31. Cheng Y, Deshmukh M, D'Costa A, Demaro JA, Gidday JM, Shah A, Sun Y, Jacquin MF, Johnson EM, and Holtzman DM (1998) Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Investig 101:1992-1999.
32. Choong IC, Lew W, Lee D, Pham P, Burdett MT, Lam JW, Wiesmann C, Luong TN, Fahr B, DeLano WL, et al. (2002) Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J Med Chem 45:5005-5022.
33. Cory S, Huang DC, and Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590-8607.
34. Crocker SJ, Wigle N, Liston P, Thompson CS, Lee CJ, Xu D, Roy S, Nicholson DW, Park DS, MacKenzie A, et al. (2001) NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease. Eur J Neurosci 14:391-400.
35. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, and Corti A (2000) Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18:1185-1190.
36. Daemen MA, van't Veer C, Denecker G, Heemskerk VH, Wolfs TG, Clauss M, Vandenabeele P, and Buurman WA (1999) Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Investig 104:541-549.
37. Daniel PT, Wieder T, Sturm I, and Schulze-Osthoff K (2001) The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 15:1022-1032.
38. Debatin KM, Poncet D, and Kroemer G (2002) Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21:8786-8803.
39. DeBiasi RL, Robinson BA, Sherry B, Bouchard R, Brown RD, Rizeq M, Long C, and Tyler KL (2004) Caspase inhibition protects against reovirus-induced myocardial injury in vitro and in vivo. J Virol 78:11040-11050.
40. Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, Caron A, Pouillart P, Wijdenes J, Rouillard D, Kroemer G, and Poupon MF (2002) Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res 62:1388-1393.
41. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, and Yuan J (2001) Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3:173-182.
42. Demjen D, Klussmann S, Kleber S, Zuliani C, Stieltjes B, Metzger C, Hirt UA, Walczak H, Falk W, Essig M, et al. (2004) Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 10:389-395.
43. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, and Reed JC (1999) Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO (Eur Mol Biol Organ) J 18:5242-5251.
44. Deveraux QL and Reed JC (1999) IAP family proteins-suppressors of apoptosis. Genes Dev 13:239-252.
45. D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, Raine CS, and Antel JP (1996) Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 184:2361-2370.
46. Eggermont AM and ten Hagen TL (2001) Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits and future perspectives. Curr Oncol Rep 3:359-367.
47. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-1038.
48. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, et al. (2001) Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 44:4313-4324.
49. Erlanson DA, Lam JW, Wiesmann C, Luong TN, Simmons RL, DeLano WL, Choong IC, Burdett MT, Flanagan WM, Lee D, et al. (2003) In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol 21:308-314.
50. Farber A, Connors JP, Friedlander RM, Wagner RJ, Powell RJ, and Cronenwett JL (1999) A specific inhibitor of apoptosis decreases tissue injury after intestinal ischemia-reperfusion in mice. J Vasc Surg 30:752-760.
51. Feng WY, Liu FT, Patwari Y, Agrawal SG, Newland AC, and Jia L (2003) BH3-domain mimetic compound BH3I-2′ induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria. Br J Haematol 121:332-340.
52. Fischer U, Janicke RU, and Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Diff 10:76-100.
53. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, and Korneluk RG (2000) Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 70:113-122.
54. Foster BA, Coffey HA, Morin MJ, and Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science (Wash DC) 286:2507-2510.
55. Friedlander RM, Gagliardini V, Hara H, Fink KB, Li W, MacDonald G, Fishman MC, Greenberg AH, Moskowitz MA, and Yuan J (1997) Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med 185:933-940.
56. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, and Fersht AR (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99:937-942.
57. Fuentes-Prior P and Salvesen GS (2004) The protein structures that shape caspase-activity, specificity, activation and inhibition. Biochem J 384:201-232.
58. Fulda S, Jeremias I, Pietsch T, Steiner HH, and Debatin KM (1999) Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 82:435-441.
59. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, and Debatin KM (1998) Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 273:33942-33948.
60. Fulda S, Wick W, Weller M, and Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808-815.
61. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA, and Leoni LM (2000) Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96:3537-3543.
62. Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, and Tavassoli M (2004) TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 23:1153-1165.
63. Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, O'Bryan E, Fumero C, Wang HG, and Bhalla K (2002) Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99:3419-3426.
64. Han BH, Xu D, Choi J, Han Y, Xanthoudakis S, Roy S, Tam J, Vaillancourt J, Colucci J, Siman R, et al. (2002) Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. J Biol Chem 277:30128-30136.
65. Han Y, Giroux A, Grimm EL, Aspiotis R, Francoeur S, Bayly CI, McKay DJ, Roy S, Xanthoudakis S, Vaillancourt JP, et al. (2004) Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors. Bioorg Med Chem Lett 14:805-808.
66. Harter WG, Albrect H, Brady K, Caprathe B, Dunbar J, Gilmore J, Hays S, Kostlan CR, Lunney B, and Walker N (2004) The design and synthesis of sulfonamides as caspase-1 inhibitors. Bioorg Med Chem Lett 14:809-812.
67. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, and Okumura K (1998) Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91:4051-4055.
68. Held J and Schulze-Osthoff K (2001) Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 4:243-252.
69. Hengartner MO (2000) The biochemistry of apoptosis. Nature (Lond) 407:770-776.
70. Hirsch T, Decaudin D, Susin SA, Marchetti P, Larochette N, Resche-Rigon M, and Kroemer G (1998) PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp Cell Res 241:426-434.
71. Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, and Contreras PC (2004) Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)- amino]-propionylamino]-4-oxo-5-(2,3 ,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted 309:
72. Hoglen NC, Hirakawa BP, Fisher CD, Weeks S, Srinivasan A, Wong AM, Valentino KL, Tomaselli KJ, Bai X, Karanewsky DS, and Contreras PC (2001) Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. J Pharmacol Exp Ther 297:811-818.
73. Holcik M, Yeh C, Korneluk RG, and Chow T (2000) Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 19:4174-4177.
74. Holinger EP, Chittenden T, and Lutz RJ (1999) Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 274:13298-13304.
75. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, et al. (2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 1:496-501.
76. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, and Karl IE (1999) Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 96:14541-14546.
77. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, and LaCasse EC (2003) Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9:2826-2836.
78. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, and Wu H (2001) Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104:781-790.
79. Ichikawa H, Ota K, and Iwata M (1996) Increased Fas antigen on T cells in multiple sclerosis. J Neuroimmunol 71:125-129.
80. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, and Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954-960.
81. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M, Ohki M, and Inazawa J (2001) Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 61:6629-6634.
82. Isabel E, Black WC, Bayly CI, Grimm EL, Janes MK, McKay DJ, Nicholson DW, Rasper DM, Renaud J, Roy S, et al. (2003) Nicotinyl aspartyl ketones as inhibitors of caspase-3. Bioorg Med Chem Lett 13:2137-2140.
83. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, and Selivanova G (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:1321-1328.
84. Jaeschke H, Farhood A, Cai SX, Tseng BY, and Bajt ML (2000) Protection against TNF-induced liver parenchymal cell apoptosis during endotoxemia by a novel caspase inhibitor in mice. Toxicol Appl Pharmacol 169:77-83.
85. James KE, Asgian JL, Li ZZ, Ekici OD, Rubin JR, Mikolajczyk J, Salvesen GS, and Powers JC (2004) Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6 and -8. J Med Chem 47:1553-1574.
86. Jia LT, Zhang LH, Yu CJ, Zhao J, Xu YM, Gui JH, Jin M, Ji ZL, Wen WH, Wang CJ, et al. (2003) Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 63:3257-3262.
87. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, Kofron J, Donnelly J, Burns D, Ng SC, Rosenberg S, and Wang X (2003) Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science (Wash DC) 299:223-226.
88. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, and Strom SC (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564-567.
89. Kam LY and Targan SR (2000) TNF-alpha antagonists for the treatment of Crohn's disease. Expert Opin Pharmacother 1:615-622.
90. Karanewsky DS, Bai X, Linton SD, Krebs JF, Wu J, Pham B, and Tomaselli KJ (1998) Conformationally constrained inhibitors of caspase-1 (interleukin-1 beta converting enzyme) and of the human CED-3 homologue caspase-3 (CPP32, apopain). Bioorg Med Chem Lett 8:2757-2762.
91. Keith FJ, Bradbury DA, Zhu YM, and Russell NH (1995) Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 9:131-138.
92. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885.
93. Kim AL, Raffo AJ, Brandt-Rauf PW, Pincus MR, Monaco R, Abarzua P, and Fine RL (1999) Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 274:34924-34931.
94. Kim KM, Giedt CD, Basanez G, O'Neill JW, Hill JJ, Han YH, Tzung SP, Zimmerberg J, Hockenbery DM, and Zhang KY (2001) Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A. Biochemistry 40:4911-4922.
95. Kleinberger T (2000) Induction of apoptosis by adenovirus E4orf4 protein. Apoptosis 5:211-215.
96. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, and Gudkov AV (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (Wash DC) 285:1733-1737.
97. Komarova EA, Neznanov N, Komarov PG, Chernov MV, Wang K, and Gudkov AV (2003) p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J Biol Chem 278:15465-15468.
98. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, et al. (2001) Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 61:5796-5802.
99. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, et al. (2003) Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9:4914-4925.
100. Ku G, Faust T, Lauffer LL, Livingston DJ, and Harding MW (1996) Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 8:377-386.
101. Kunstle G, Leist M, Uhlig S, Revesz L, Feifel R, MacKenzie A, and Wendel A (1997) ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. Immunol Lett 55:5-10.
102. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J, and Kroemer G (1999) Arsenite induces apoptosis via a direct effect on the mitochondrial permeability pore. Exp Cell Res 249:413-421.
103. Lavoie JN, Nguyen M, Marcellus RC, Branton PE, and Shore GC (1998) E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J Cell Biol 140:637-645.
104. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, et al. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385.
105. Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, Kikly K, Winkler JD, Sung CM, Debouck C, et al. (2000) Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem 275:16007-16014.
106. Li H, Colbourne F, Sun P, Zhao Z, Buchan AM, and Iadecola C (2000) Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats. Stroke 31:176-182.
107. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, and Harran PG (2004) A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science (Wash DC) 305:1471-1474.
108. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, and Salfeld J (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80:401-411.
109. Linton SD, Aja T, Allegrini PR, Deckwerth TL, Diaz JL, Hengerer B, Herrmann J, Jahangiri KG, Kallen J, Karanewsky DS, et al. (2004) Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke. Bioorg Med Chem Lett 14:2685-2691.
110. Linton SD, Karanewsky DS, Ternansky RJ, Chen N, Guo X, Jahangiri KG, Kalish VJ, Meduna SP, Robinson ED, Ullman BR, et al. (2002a) Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization. Bioorg Med Chem Lett 12:2973-2975.
111. Linton SD, Karanewsky DS, Ternansky RJ, Wu JC, Pham B, Kodandapani L, Smidt R, Diaz JL, Fritz LC, and Tomaselli KJ (2002b) Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization. Bioorg Med Chem Lett 12: 2969-2971.
112. Los M, Stroh C, Janicke RU, Engels IH, and Schulze-Osthoff K (2001) Caspases: more than just killers? Trends Immunol 22:31-34.
113. Los M, Wesselborg S, and Schulze-Osthoff K (1999) The role of caspases in development, immunity and apoptotic signal transduction: lessons from knockout mice. Immunity 10:629-639.
114. Maaser K, Hopfner M, Jansen A, Weisinger G, Gavish M, Kozikowski AP, Weizman A, Carayon P, Riecken EO, Zeitz M, and Scherubl H (2001) Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer 85:1771-1780.
115. MacCorkle RA, Freeman KW, and Spencer DM (1998) Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci USA 95:3655-3660.
116. Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, Costantini P, Metivier D, Susin SA, Kroemer G, and Formstecher P (1999) The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 59:6257-6266.
117. Martin-Villalba A, Hahne M, Kleber S, Vogel J, Falk W, Schenkel J, and Krammer PH (2001) Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Diff 8:679-686.
118. Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, and Hainaut P (2001) Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20:3533-3540.
119. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, Morris SJ, Durkin JP, and Lacasse EC (2004) Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23:8105-8117.
120. Meng L, Kwok BH, Sin N, and Crews CM (1999a) Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 59:2798-2801.
121. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, and Crews CM (1999b) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96:10403-10408.
122. Mesri M, Wall NR, Li J, Kim RW, and Altieri DC (2001) Cancer gene therapy using a survivin mutant adenovirus. J Clin Investig 108:981-990.
123. Micheau O and Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190.
124. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, et al. (2002) Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99:3461-3464.
125. Miller BE, Krasney PA, Gauvin DM, Holbrook KB, Koonz DJ, Abruzzese RV, Miller RE, Pagani KA, Dolle RE, and Ator MA (1995) Inhibition of mature IL-1 beta production in murine macrophages and a murine model of inflammation by WIN 67694, an inhibitor of IL-1 beta converting enzyme. J Immunol 154:1331-1338.
126. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, et al. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 9:14374-14379.
127. Modica-Napolitano JS, Koya K, Weisberg E, Brunelli BT, Li Y, and Chen LB (1996) Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. Cancer Res 56:544-550.
128. Nakashima T, Miura M, and Hara M (2000) Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. Cancer Res 60:1229-1235.
129. Natori S, Higuchi H, Contreras P, and Gores GJ (2003) The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transpl 9:278-284.
130. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, Strober W, and Kollias G (1997) Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27:1743-1750.
131. Nguyen JT and Wells JA (2003) Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc Natl Acad Sci USA 100:7533-7538.
132. Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, Wang R, Fang X, Guo R, Zhang M, et al. (2004) Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 47:2430-2440.
133. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, and Zipp F (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356:827-828.
134. Nobel CS, Kimland M, Nicholson DW, Orrenius S, and Slater AF (1997) Disulfiram is a potent inhibitor of proteases of the caspase family. Chem Res Toxicol 10:1319-1324.
135. Nor JE, Hu Y, Song W, Spencer DM, and Nunez G (2002) Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Ther 9:444-451.
136. Okamoto Y, Anan H, Nakai E, Morihira K, Yonetoku Y, Kurihara H, Sakashita H, Terai Y, Takeuchi M, Shibanuma T, and Isomura Y (1999) Peptide based interleukin-1 beta converting enzyme (ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the ICE-inhibitor complex. Chem Pharm Bull (Tokyo) 47:11-21.
137. Okuda Y, Sakoda S, Fujimura H, Nagata S, Yanagihara T, and Bernard CC (2000) Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 275:164-168.
138. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature (Lond) 399:263-267.
139. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, et al. (2004) Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47:4417-4426.
140. Pietersen A and Noteborn HM (2000) Apoptin. Adv Exp Med Biol 465:153-161.
141. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, and Brown DM (1995) Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1:1046-1051.
142. Puthalakath H and Strasser A (2002) Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Diff 9:505-512.
143. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsch F, Goulbern M, Poupon MF, Miccoli L, et al. (1999) Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18:2537-2546.
144. Reed JC and Bischoff JR (2000) BIRinging chromosomes through cell division-and survivin' the experience. Cell 102:545-548.
145. Reed JC, Cuddy M, Haldar S, Croce C, Nowell P, Makover D, and Bradley K (1990a) BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc Natl Acad Sci USA 87:3660-3664.
146. Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S, and Cohen J (1990b) Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50:6565-6570.
147. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617.
148. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, Liddington RC, and Salvesen GS (2001) Structural basis for the inhibition of caspase-3 by XIAP. Cell 104:791-800.
149. Roberts DL, Merrison W, MacFarlane M, and Cohen GM (2001) The inhibitor of apoptosis protein-binding domain of Smac is not essential for its proapoptotic activity. J Cell Biol 153:221-228.
150. Rodriguez I, Matsuura K, Ody C, Nagata S, and Vassalli P (1996) Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 184:2067-2072.
151. Rohn JL and Noteborn MH (2004) The viral death effector Apoptin reveals tumor-specific processes. Apoptosis 9:315-322.
152. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J, Ashkenazi A, and Weller M (1999) Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 265:479-483.
153. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, and zur Hausen H (1998) Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72:9470-9478.
154. Roy S, Bayly CI, Gareau Y, Houtzager VM, Kargman S, Keen SL, Rowland K, Seiden IM, Thornberry NA, and Nicholson DW (2001) Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc Natl Acad Sci USA 98:6132-6137.
155. Rozman-Pungercar J, Kopitar-Jerala N, Bogyo M, Turk D, Vasiljeva O, Stefe I, Vandenabeele P, Bromme D, Puizdar V, Fonovic M, et al. (2003) Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity. Cell Death Diff 10:881-888.
156. Salvesen GS and Duckett CS (2002) IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410.
157. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, and Patel J (2004a) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53:1485-1493.
158. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, and Jeche R (2004b) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99:1984-1989.
159. Sandborn WJ and Hanauer SB (1999) Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 5:119-133.
160. Sasaki H, Sheng Y, Kotsuji F, and Tsang BK (2000) Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60:5659-5666.
161. Scallon BJ, Moore MA, Trinh H, Knight DM, and Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251-259.
162. Scheffner M, Huibregtse JM, Vierstra RD, and Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
163. Scheinfeld N (2004) A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 15:280-294.
164. Schimmer AD, Hedley DW, Chow S, Pham NA, Chakrabartty A, Bouchard D, Mak TW, Trus MR, and Minden MD (2001) The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Diff 8:725-733.
165. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, et al. (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5:25-35.
166. Schotte P, Declercq W, Van Huffel S, Vandenabeele P, and Beyaert R (1999) Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 442: 117-121.
167. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, and Peter ME (1998) Apoptosis signaling by death receptors. Eur J Biochem 254:439-459.
168. Schwerk C and Schulze-Osthoff K (2003) Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem Pharmacol 66:1453-1458.
169. Scott CW, Sobotka-Briner C, Wilkins DE, Jacobs RT, Folmer JJ, Frazee WJ, Bhat RV, Ghanekar SV, and Aharony D (2003) Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis. J Pharmacol Exp Ther 304:433-440.
170. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, and Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3:632-638.
171. Selivanova G, Ryabchenko L, Jansson E, Iotsova V, and Wiman KG (1999) Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 19:3395-3402.
172. Seth P, Brinkmann U, Schwartz GN, Katayose D, Gress R, Pastan I, and Cowan K (1996) Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res 56:1346-1351.
173. Shahripour AB, Plummer MS, Lunney EA, Albrecht HP, Hays SJ, Kostlan CR, Sawyer TK, Walker NP, Brady KD, Allen HJ, et al. (2002) Structure-based design of nonpeptide inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). Bioorg Med Chem 10:31-40.
174. Shangary S and Johnson DE (2002) Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release and activation of cell death. Biochemistry 41:9485-9495.
175. Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, and Slawin KM (2001) Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. Cancer Res 61:2562-2571.
176. Silke J, Hawkins CJ, Ekert PG, Chew J, Day CL, Pakusch M, Verhagen AM, and Vaux DL (2002) The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. J Cell Biol 157:115-124.
177. Springer JE, Azbill RD, and Knapp PE (1999) Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat Med 5:943-946.
178. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Muhlhahn P, et al. (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40:336-344.
179. Sun C, Cai M, Meadows RP, Xu N, Gunasekera AH, Herrmann J, Wu JC, and Fesik SW (2000) NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 275:33777-33781.
180. Sun H, Nikolovska-Coleska Z, Yang CY, Xu L, Tomita Y, Krajewski K, Roller PP, and Wang S (2004) Structure-based design, synthesis and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem 47:4147-4150.
181. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, Ludwig WD, and Wuchter C (2004) High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 10:3737-3744.
182. Tamm I, Trepel M, Cardo-Vila M, Sun Y, Welsh K, Cabezas E, Swatterthwait A, Arap W, Reed JC, and Pasqualini R (2003) Peptides targeting caspase inhibitors. J Biol Chem 278:14401-14405.
183. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, and Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029-1035.
184. Taylor JK, Zhang QQ, Wyatt JR, and Dean NM (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 17:1097-1100.
185. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, and Aunins J (1992) A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature (Lond) 356:768-774.
186. Tinhofer I, Anether G, Senfter M, Pfaller K, Bernhard D, Hara M, and Greil R (2002) Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tetrocarcin-A. FASEB J 16:1295-1297.
187. Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, O'Donnell R, Tam J, Han Y, Colucci J, Giroux A, et al. (2004) Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br J Pharmacol 141:689-697.
188. Tse E and Rabbitts TH (2000) Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy. Proc Natl Acad Sci USA 97:12266-12271.
189. Tsukada N, Kobata T, Aizawa Y, Yagita H, and Okumura K (1999) Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93:2738-2747.
190. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY, and Hockenbery DM (2001) Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3:183-191.
191. Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, and Dixit VM (2000a) Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 6:961-967.
192. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, and Choo KH (2000b) Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10:1319-1328.
193. Valentino KL, Gutierrez M, Sanchez R, Winship MJ, and Shapiro DA (2003) First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 41:441-449.
194. van der Eb MM, Pietersen AM, Speetjens FM, Kuppen PJ, van de Velde CJ, Noteborn MH, and Hoeben RC (2002) Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther 9:53-61.
195. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (Wash DC) 303:844-848.
196. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, and French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (Wash DC) 282:490-493.
197. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, and Dowdy SF (1999) Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 5:29-33.
198. von Coelln R, Kugler S, Bahr M, Weller M, Dichgans J, and Schulz JB (2001) Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. J Neurochem 77:263-273.
199. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, and Dixit VM (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10:1359-1366.
200. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163.
201. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, and Korsmeyer SJ (2004) Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (Wash DC) 305:1466-1470.
202. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, and Huang Z (2000a) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97:7124-7129.
203. Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R, and Huang Z (2000b) Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 60:1498-1502.
204. Wang Y, Huang JC, Zhou ZL, Yang W, Guastella J, Drewe J, and Cai SX (2004a) Dipeptidyl aspartyl fluoromethylketones as potent caspase-3 inhibitors: SAR of the P2 amino acid. Bioorg Med Chem Lett 14:1269-1272.
205. Wang Z, Cuddy M, Samuel T, Welsh K, Schimmer A, Hanaii F, Houghten R, Pinilla C, and Reed JC (2004b) Cellular, biochemical and genetic analysis of mechanism of small-molecule IAP inhibitors. J Biol Chem 279:48168-48176.
206. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, and Shi Y (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature (Lond) 408:1008-1012.
207. Wu JC and Fritz LC (1999) Irreversible caspase inhibitors: tools for studying apoptosis. Methods 17:320-328.
208. Wu TY, Wagner KW, Bursulaya B, Schultz PG, and Deveraux QL (2003) Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem Biol 10:759-767.
209. Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, and Spencer DM (2001) Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res 61:6795-6804.
210. Xu D, Bureau Y, McIntyre DC, Nicholson DW, Liston P, Zhu Y, Fong WG, Crocker SJ, Korneluk RG, and Robertson GS (1999) Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J Neurosci 19:5026-5033.
211. Xu DG, Crocker SJ, Doucet JP, St-Jean M, Tamai K, Hakim AM, Ikeda JE, Liston P, Thompson CS, Korneluk RG, et al. (1997) Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat Med 3:997-1004.
212. Xu YM, Wang LF, Jia LT, Qiu XC, Zhao J, Yu CJ, Zhang R, Zhu F, Wang CJ, Jin BQ, et al. (2004) A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol 173:61-67.
213. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, and Korsmeyer SJ (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285-291.
214. Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, Yamori T, Oh-Hara T, and Tsuruo T (2003a) Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 63:831-837.
215. Yang L, Sugama S, Mischak RP, Kiaei M, Bizat N, Brouillet E, Joh TH, and Beal MF (2004) A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate and 3NP in vivo. Neurobiol Dis 17:250-259.
216. Yang W, Guastella J, Huang JC, Wang Y, Zhang L, Xue D, Tran M, Woodward R, Kasibhatla S, Tseng B, et al. (2003b) MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. Br J Pharmacol 140:402-412.
217. Yang Y, Fang S, Jensen JP, Weissman AM, and Ashwell JD (2000) Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (Wash DC) 288:874-877.
218. Yaoita H, Ogawa K, Maehara K, and Maruyama Y (1998) Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 97:276-281.
219. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH, Natt F, Haner R, Martin P, Hall J, et al. (2000) A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 6:2547-2555.
220. Zhang HZ, Kasibhatla S, Wang Y, Herich J, Guastella J, Tseng B, Drewe J, and Cai SX (2004) Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 12:309-317.